Aptevo Reports 85% Remission in Q2
Aptevo Therapeutics (NASDAQ:APVO), a clinical-stage immuno-oncology company focusing on innovative antibody therapies for cancer, reported second quarter results on August 11, 2025, covering the three months ended June 30. The key highlight was a net loss per share of $8.40 (GAAP), a much smaller loss than analyst estimates of $83.20 per share (GAAP). The company again reported zero revenue, consistent with its current pre-commercial status. Notably, remission rates for its lead candidate mipletamig in acute myeloid leukemia (AML) reached 85% across two combination therapy trials. With solid clinical progress, a fresh capital raise, and cash reserves rising to $9.41 million, the quarter marked a period of decisive strategic and financial movement for Aptevo.
Source: Analyst estimates for the quarter provided by FactSet.
Aptevo Therapeutics develops next-generation immune system antibodies used to target and treat various cancers. Its current clinical and preclinical pipeline includes therapies for acute myeloid leukemia, multiple solid tumors, and prostate cancer. Two proprietary technology platforms, ADAPTIR and ADAPTIR-FLEX, allow the company to design bispecific and multi-specific antibodies with the aim of improving both efficacy and safety compared to older approaches.
Source Fool.com
